Published in Am J Obstet Gynecol on January 17, 2013
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol (2013) 0.86
Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2015) 0.85
Interstitial pregnancy resulting in a viable infant coexistent with massive perivillous fibrin deposition: a case report and literature review. AJP Rep (2014) 0.84
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol (2015) 0.80
Placental lesions associated with acute atherosis. J Matern Fetal Neonatal Med (2014) 0.77
Prenatal diagnosis of a placental infarction hematoma associated with fetal growth restriction, preeclampsia and fetal death: clinicopathological correlation. Fetal Diagn Ther (2014) 0.75
Adverse Pregnancy Outcomes of Patients with History of First-Trimester Recurrent Spontaneous Abortion. Biomed Res Int (2017) 0.75
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Mechanisms of angiogenesis. Nature (1997) 18.04
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Defective angiogenesis in mice lacking endoglin. Science (1999) 4.40
1994-1996 U.S. singleton birth weight percentiles for gestational age by race, Hispanic origin, and gender. Matern Child Health J (1999) 3.41
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med (2000) 3.25
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol (2004) 2.72
A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest (1999) 2.64
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol (2000) 2.50
Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation (2007) 2.35
Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab (2003) 2.07
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol (2009) 1.92
Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab (2003) 1.88
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol (1998) 1.79
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol (2003) 1.67
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A (2010) 1.56
Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. Pediatr Dev Pathol (2002) 1.53
The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol (2011) 1.50
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50
Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol (2003) 1.48
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol (2009) 1.44
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep (2008) 1.42
Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol (2001) 1.42
Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. J Exp Zool (1989) 1.42
THE PATHOGENIC ROLE OF FIBRIN DEPOSITION IN THE GLOMERULAR LESIONS OF TOXEMIA OF PREGNANCY. J Exp Med (1963) 1.42
Maternal floor infarction of the placenta: association with central nervous system injury and adverse neurodevelopmental outcome. J Perinatol (2002) 1.41
Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol (1997) 1.40
Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol (1999) 1.35
Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol (2007) 1.34
Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol (2006) 1.32
Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol (2007) 1.29
Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol (2007) 1.28
Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol (2006) 1.28
Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) (2007) 1.22
Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol (2007) 1.20
Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol (2001) 1.19
Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol (2006) 1.16
Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension (2012) 1.14
Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension (2007) 1.13
Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med (2011) 1.13
Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med (2005) 1.12
Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol (2011) 1.11
A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonatal Med (2009) 1.09
A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med (2006) 1.08
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol (2006) 1.07
Trophoblast interaction with fibrin matrix. Epithelialization of perivillous fibrin deposits as a mechanism for villous repair in the human placenta. Am J Pathol (1990) 1.05
An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol (2005) 1.05
Placental morphometrical and histopathology changes in the different clinical presentations of hypertensive syndromes in pregnancy. Arch Gynecol Obstet (2007) 1.04
Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol (1997) 1.03
Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med (2008) 1.03
Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol (2007) 1.00
Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension (2010) 0.99
Allelic variations in angiogenic pathway genes are associated with preeclampsia. Am J Obstet Gynecol (2010) 0.99
Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol (2011) 0.98
Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol (2007) 0.97
Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta (2008) 0.96
Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol (2007) 0.96
An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med (2010) 0.95
Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol (2007) 0.95
Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med (2007) 0.94
Massive perivillous fibrinoid causing recurrent placental failure. BJOG (2003) 0.92
Maternal floor infarction: relationship to X cells, major basic protein, and adverse perinatal outcome. Am J Obstet Gynecol (1992) 0.92
Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med (2008) 0.92
Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol (2008) 0.92
Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. J Pregnancy (2011) 0.91
Immunohistochemistry of two different types of placental fibrinoid. Acta Anat (Basel) (1994) 0.90
Maternal vascular lesions in pre-eclampsia and intrauterine growth retardation: light microscopy and immunofluorescence. Placenta (1983) 0.89
Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest (1996) 0.88
Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril (2009) 0.88
Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol (2010) 0.86
A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol (2010) 0.85
Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. J Matern Fetal Neonatal Med (2010) 0.85
Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. Am J Obstet Gynecol (2012) 0.84
Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome. Transl Res (2012) 0.84
Maternal floor infarction. Hum Pathol (1985) 0.83
Cytomegalovirus-induced mirror syndrome associated with elevated levels of angiogenic factors. Obstet Gynecol (2007) 0.83
Recurrent maternal floor infarction: a preventable cause of fetal death. Am J Obstet Gynecol (1983) 0.82
Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med (2010) 0.82
Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes. Obstet Gynecol (2012) 0.82
Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. BJOG (2002) 0.81
Recurrent placental massive perivillous fibrin deposition associated with polymyositis: a case report and review of the literature. Pediatr Dev Pathol (2007) 0.81
Activated protein C resistance associated with maternal floor infarction treated with low-molecular-weight heparin. Am J Perinatol (2002) 0.80
Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol (2010) 0.80
Role of tissue factor in pregnancy complications: crosstalk between coagulation and inflammation. Thromb Res (2011) 0.80
Ontogenetic and phylogenetic evaluation of the presence of fibrin-type fibrinoid in the villous haemochorial placenta. Placenta (1997) 0.80
Maternal floor infarction in autoimmune disease: two cases. Pediatr Pathol Lab Med (1997) 0.79
Epidemiology and causes of preterm birth. Lancet (2008) 18.96
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
A systems biology approach for pathway level analysis. Genome Res (2007) 6.95
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One (2008) 3.01
Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol (2011) 2.95
Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet (2008) 2.90
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Machine learning and its applications to biology. PLoS Comput Biol (2007) 2.57
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 2.42
The fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 2.36
Onto-Tools: new additions and improvements in 2006. Nucleic Acids Res (2007) 2.33
The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome (2014) 2.24
Listeriosis in human pregnancy: a systematic review. J Perinat Med (2011) 2.20
The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol (2006) 2.11
Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: a systematic review. Diabetes Res Clin Pract (2012) 2.07
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
Evolution of the mammalian placenta revealed by phylogenetic analysis. Proc Natl Acad Sci U S A (2006) 1.89
Genomics, biogeography, and the diversification of placental mammals. Proc Natl Acad Sci U S A (2007) 1.86
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate (2006) 1.86
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. J Perinat Med (2006) 1.82
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Infection and prematurity and the role of preventive strategies. Semin Neonatol (2002) 1.78
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol (2010) 1.77
Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol (2009) 1.77
Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol (2010) 1.75
Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol (2010) 1.74
Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol (2006) 1.73
Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.69
Gene-centric genomewide association study via entropy. Genetics (2008) 1.68
Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.65
Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol (2004) 1.64
A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol (2005) 1.64
Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J Matern Fetal Neonatal Med (2007) 1.62
Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol (2004) 1.60
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Intrauterine endotoxin administration leads to white matter diffusivity changes in newborn rabbits. J Child Neurol (2009) 1.58
Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol (2002) 1.58
Structural and functional comparison of mast cells in the pregnant versus nonpregnant human uterus. Am J Obstet Gynecol (2006) 1.54
The clinical significance of a positive Amnisure test in women with term labor with intact membranes. J Matern Fetal Neonatal Med (2009) 1.54
A systematic approach to the use of the multiplanar display in evaluation of abnormal vascular connections to the fetal heart using 4-dimensional ultrasonography. J Ultrasound Med (2007) 1.53
Analysis of microarray experiments of gene expression profiling. Am J Obstet Gynecol (2006) 1.53
The ninety-fifth percentile for growth discordance predicts complications of twin pregnancy. Am J Obstet Gynecol (2002) 1.53
Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol (2004) 1.51
Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol (2009) 1.50
The evolution of menstruation: a new model for genetic assimilation: explaining molecular origins of maternal responses to fetal invasiveness. Bioessays (2011) 1.50
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50
Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol (2004) 1.49
The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med (2010) 1.48
A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol (2005) 1.48
Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol (2007) 1.47
Randomized trial of a comprehensive asthma education program after an emergency department visit. Ann Allergy Asthma Immunol (2006) 1.47
The risk of impending preterm delivery in asymptomatic patients with a nonmeasurable cervical length in the second trimester. Am J Obstet Gynecol (2010) 1.45
A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. J Biol Chem (2001) 1.42
A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity. PLoS One (2013) 1.41
Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered (2006) 1.41
Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics (2013) 1.39
Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol (2010) 1.39
Intrauterine infection and the development of cerebral palsy. BJOG (2003) 1.39
The clinical significance of detecting Ureaplasma urealyticum by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. Am J Obstet Gynecol (2003) 1.38
TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. J Immunol (2009) 1.37